<DOC>
	<DOCNO>NCT01677728</DOCNO>
	<brief_summary>The aim study explore whether target therapy combination chemotherapy treatment could improve survival tumor response patient undergo Synchronic Hepatectomy Colorectal Liver Metastases .</brief_summary>
	<brief_title>Effect Target Therapy Patients Undergoing Synchronic Hepatectomy Colorectal Liver Metastases</brief_title>
	<detailed_description>In patient colorectal cancer ( CRC ) , liver common site hematogenous metastasis . Approximately half patient develop hepatic metastasis course disease , hepatic metastasis responsible death least two third CRC patient . Over past decade , due introduction irinotecan-based oxaliplatin-based combination chemotherapy , median survival among patient colorectal liver metastasis ( CLM ) increase 6 ~8 month 20 months5.In recent year , target therapy rapidly gain attention treatment CLM active investigation . Although numerous publication report efficacy target therapy combination treatment CLM patient , study focus solely patient without undergo resection liver metastasis . In contrast , little work concentrate explore effection target therapy CLM patient undergo Synchronic Hepatectomy .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>age 18 75 year old Performance status ( ECOG ) 0~1 colorectal adenocarcinoma pathologically without chemotherapy radiotherapy liver metastases undergoing radical resection colorectal cancer undergo radical resection metastasis suitable chemotherapy agree patient age 18 year old great 75 year old n't pathological diagnosis colorectal adenocarcinoma liver metastase chemotherapy radiotherapy metastasis unresectable colorectal cancer liver metastases unsuitable chemotherapy target therapy agree patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>colorectal liver metastasis</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>cetuximab</keyword>
	<keyword>bevacizumab</keyword>
</DOC>